Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges

Area of Science:

• Urology
• Oncology
• Diagnostic Imaging

Background:

• Prostate-specific antigen (PSA) is a key biomarker for prostate cancer detection.
• Age-specific reference ranges for PSA levels are used to account for age-related increases in PSA.
• Prostate volume also influences PSA levels, potentially confounding age-specific interpretations.

Purpose of the Study:

• To evaluate the role of prostate-specific antigen density (PSAD) in early prostate cancer detection.
• To assess if age-specific PSA reference ranges adequately account for prostate volume.
• To determine if PSAD can help reduce unnecessary prostate biopsies.

Main Methods:

• Retrospective review of 2429 patients aged 40-79 years undergoing transrectal ultrasound (TRUS).
• Analysis of serum PSA levels, prostate volume, and digital rectal examination (DRE) findings.
• Calculation of PSAD and assessment of biopsy outcomes based on PSAD thresholds.

Main Results:

• Serum PSA and prostate volume increase with age, with volume having a stronger association (r=0.46).
• Prostate volume explained 18% of PSA variation, while age explained only 2%.
• Using PSAD < 0.15 in patients with negative DRE/TRUS and PSA 10.0 ng/mL or less resulted in a low cancer detection rate (1.9%) and fewer biopsies.

Conclusions:

• Age-specific PSA ranges do not fully account for prostate volume's effect on PSA levels.
• PSAD remains a valuable tool for safely reducing the number of biopsies needed.
• PSAD assists in risk stratification for patients with elevated PSA and negative DRE/TRUS findings.